As activated AKT/mTOR and Ras/MAPK signaling cascades are frequently and concomitantly observed in human HCC [24] as well as in AKT/c-MET hepatocellular lesions [24], we hypothesized that MEK and/or AKT/mTOR inhibitors might be effective for HCC treatment. Here, MET is linked to hepatocellular carcinoma.